Welcome to our store!

New collections added on a weekly basis!

Now Accepting FSA & HSA cards

FREE SHIPPING

for all orders over $99.99 within the CONTINENTAL USA.

Management of Iron Toxicity

David Manthey, MD |

iron-toxicityPrepublication-and-ExpertPeerReviewIron toxicity is determined by the amount of elemental iron (Fe) ingested. Examples of Fe formulations and the amount of elemental Fe contained in each formulation are listed in the table below (adapted from 1).

 

Contents Elemental Fe (%)
Ferrous chloride 28
Ferrous fumarate 33
Ferrous gluconate 12
Ferrous lactate 19
Ferrous sulfate 20

Calculating amount of elemental Fe ingested

Multiply the total Fe content in each tablet by the percentage of elemental Fe for the product formulation. For example, the elemental iron equivalent calculation for 80 tablets of Ferrous Sulfate is: 325 mg Fe/tablet x 20% elemental Fe/tablet = 65 mg elemental Fe/tablet. The total elemental Fe ingested is: (65 mg/tab x 80 tablets) /50 kg = 104 mg/kg. Notable levels for elemental Fe include:

  • >20 mg/kg Gastrointestinal symptoms start
  • ≥40 mg/kg Current level recommended for ED referral after ingestion2

Pharmacology and Toxicology

Humans do not synthesize or secrete Fe. Total body Fe is regulated via absorption from the gastrointestinal tract. Absorption occurs in the duodenum, where Fe is stored as ferritin in the intestinal cells. It is then disposed of via epithelial cell shedding or, depending on the body’s need, can be released to transferrin, a serum Fe-binding protein. In Fe overdoses, the corrosive effects of Fe on the GI tract mucosa permit passive absorption of Fe. Once transferrin is saturated, “free” Fe is available to cause toxicity. Iron causes toxicity thru several mechanisms, including3:

  • Engages in redox reactions with the formation of free radicals and oxidative damage
  • Alters cellular energy and metabolism
  • Uncouples oxidative phosphorylation
  • Ultimately results in cellular death

Iron Toxicity: Presentation

Classically, five stages of iron toxicity are described (adapted from 4):

Stage Timing post-ingestion Symptoms of Iron Toxicity
1 0.5-6 hours Local toxicity: Nausea, vomiting, diarrhea; abdominal pain, gastrointestinal bleeding
2 6-24 hours Latent toxicity: Resolution of local toxicity with ongoing cellular toxicity, hypovolemia, poor tissue perfusion (metabolic acidosis, ↑ lactate levels)
3 12-24 hours Shock, acidosis, coagulopathy, coma, multisystem organ failure
4 2-3 days Hepatic failure (periportal)
5 3-6 weeks Sequelae: Gastric outlet obstruction, small bowel obstruction

The lack of vomiting early after an ingestion (during stage I) has important clinical significance. If no vomiting has occurred within 6 hours after ingestion, then the patient likely did not ingest a toxic dose. This patient can be medically cleared.2

Laboratory Testing

For most preparations, a peak Fe level occurs 2–6 hours post-ingestion. The peak level predicts severity of iron toxicity and guides management decisions (see table below). After 6 hours, Fe distributes out of the intravascular compartment, and levels are less useful for predicting toxicity.1 Additional lab tests to consider obtaining include:

  • Basic metabolic panel
  • Lactate
  • Complete blood count (CBC)
  • Coagulation tests (PT/INR/PTT)
  • Liver function tests (LFT)

Total iron binding capacity (TIBC), glucose, and WBC counts are unreliable in predicting iron toxicity.4 The radiopacity of Fe varies with the preparation, time since ingestion, and amount of ingestion. If pill fragments are visualized on the KUB, then administration of whole bowel irrigation (WBI) may limit further absorption of Fe. However, a normal KUB does not exclude ingestion.

Serum Iron Level (mcg/dL) Clinical Symptoms of Iron Toxicity
<300 Lacks significant clinical effect
300-499 Mild – moderate: nausea, vomiting, diarrhea; mild systemic symptoms; serious toxicity unlikely
500-1000 Moderate – Severe systemic toxicity
>1000 Significant morbidity and mortality

Initial Treatment

The treatment of Fe overdose starts with attention to supportive care and adequate fluid resuscitation.

  1. Isotonic fluids: Numerous reasons account for hypovolemia and poor perfusion. Start fluid resuscitation with isotonic fluid boluses to restore hypovolemia.
  2. Activated charcoal (or other oral complexing agents): This is INEFFECTIVE at binding Fe to limit absorption.2,5
  3. Whole bowel irrigation: This may be considered when Fe tablets are visualized on the KUB film. However, no controlled studies support the efficacy of WBI and so individual risks and benefits should be considered. WBI is achieved by administration of polyethylene glycol (PEG) solution via NG tube at recommended rates of 500 mL/hr in children and 1.5 – 2 L/hr in adolescents and adults.6
  4. Gastric lavage: Generally NOT recommended7

 

Antidote: Deferoxamine (DFO)

DFO is a chelator with high affinity and specificity for Fe. After chelation with Fe, it forms a stable compound ferrioxamine that is excreted in the urine. Indications for use in acute Fe toxicity are not well defined, or based on controlled studies, and are expert consensus derived. General indications for intravenous DFO administration include ANY of the following:

  • Fe level > 500 mcg/dl
  • Presence of metabolic acidosis
  • Lethargy/coma
  • Shock
  • Toxic appearance

Unfortunately, no study has determined the optimal dosing regimen, maximum dose, or length of administration. As such, consultation with a toxicologist for dosing administration and duration is recommended. Side effects from DFO:

  • Acute, rate related side effects of DFO include urticaria and hypotension. Thus adequate fluid resuscitation prior to initiation of DFO is important.
  • A late side effect is Yersinia sepsis. DFO is a siderophore that fosters the growth of Yersinia, accounting for sepsis.
  • ARDS has been noted with prolonged DFO infusions > 24 hours.

Outdated Practice Regarding Deferoxamine

Ferrioxamine is a brick-orange color (AKA vin rose). Two antiquated recommendations guiding the administration of DFO relate to visualizing vin rose in the urine. The first is to administer a DFO challenge (IM shot); if vin rose is present in urine, then continue with further DFO treatment. The second is to continue DFO until vin rose in the urine clears. Both practices have been abandoned secondary to lack of reliability.1,4

1.
Madiwale T, Liebelt E. Iron: not a benign therapeutic drug. Curr Opin Pediatr. 2006;18(2):174-179. [PubMed]
2.
Manoguerra A, Erdman A, Booze L, et al. Iron ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2005;43(6):553-570. [PubMed]
3.
Mills K, Curry S. Acute iron poisoning. Emerg Med Clin North Am. 1994;12(2):397-413. [PubMed]
4.
Chang T, Rangan C. Iron poisoning: a literature-based review of epidemiology, diagnosis, and management. Pediatr Emerg Care. 2011;27(10):978-985. [PubMed]
5.
Matteucci M, Habibe M, Robson K, Baldassano A, Riffenburgh R, Tanen D. Effect of oral calcium disodium EDTA on iron absorption in a human model of iron overdose. Clin Toxicol (Phila). 2006;44(1):39-43. [PubMed]
6.
Position paper: whole bowel irrigation. J Toxicol Clin Toxicol. 2004;42(6):843-854. [PubMed]
7.
Benson B, Hoppu K, Troutman W, et al. Position paper update: gastric lavage for gastrointestinal decontamination. Clin Toxicol (Phila). 2013;51(3):140-146. [PubMed]

Author information

David Manthey, MD

David Manthey, MD

Professor of Emergency Medicine Wake Forest University Baptist Medical Center

The post Management of Iron Toxicity appeared first on ALiEM.

Escribir un comentario

Tenga en cuenta que los comentarios se tienen que aprobar antes de que se publiquen.